Alimta

... Research and Markets: More People Die of Lung Cancer Than of Colon, Breast, and Prostate Cancers Combined Research and Markets: More People Die of Lung Cancer Than of Colon, Breast, and Prostate Cancers Combined DUBLIN, Ireland, June 9 /PRNewswire/ - Research and Markets (http://www.researchandmarkets.com/reports/c18898 ) has announced the addition of Lung Cancer Outlook to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world.

According to American Cancer Society predictions, 173,770 will be diagnosed and 160,440 people will die by lung cancer in 2004.

In the year 2002, over 800,000 people worldwide died of non-small cell lung cancer (NSCLC).

More people die of lung cancer than of colon, breast, and prostate cancers combined.

This issue of Cancer Highlights studies the progress of the most pronounced anti-cancer drugs in development for the treatment of NSCLC.

Several unfavorable results have been the reality for many drugs.

But, in contrary Eli Lilly's More than 200 companies have been identified that have, or have had, drugs under therapeutic development in patients with lung cancer in one form or the other.

Of these, approximately 30 companies are conducting phase III trials for lung cancer.

These late stage investigational drugs are the most discussed drugs durin...

Read more...